TY - JOUR
T1 - Viral load is associated with mitochondrial dysfunction and altered monocyte phenotype in acute severe SARS-CoV-2 infection
AU - Romão, Pedro RT
AU - Teixeira, Paula C.
AU - Schipper, Lucas
AU - da Silva, Igor
AU - Santana Filho, Paulo
AU - Júnior, Luiz Carlos Rodrigues
AU - Peres, Alessandra
AU - Gonçalves da Fonseca, Simone
AU - Chagas Monteiro, Marta
AU - Lira, Fabio S.
AU - Andrey Cipriani Frade, Marco
AU - Comerlato, Juliana
AU - Comerlato, Carolina
AU - Sant'Anna, Fernando Hayashi
AU - Bessel, Marina
AU - Abreu, Celina Monteiro
AU - Wendland, Eliana M.
AU - Dorneles, Gilson P.
N1 - Publisher Copyright:
© 2022
PY - 2022/7
Y1 - 2022/7
N2 - Monocytes play a major role in the initial innate immune response to SARS-CoV-2. Although viral load may correlate with several clinical outcomes in COVID-19, much less is known regarding their impact on innate immune phenotype. We evaluated the monocyte phenotype and mitochondrial function in severe COVID-19 patients (n = 22) with different viral burden (determined by the median of viral load of the patients) at hospital admission. Severe COVID-19 patients presented lower frequency of CD14 + CD16- classical monocytes and CD39 expression on CD14 + monocytes, and higher frequency of CD14 + CD16 + intermediate and CD14-CD16 + nonclassical monocytes as compared to healthy controls independently of viral load. COVID-19 patients with high viral load exhibited increased GM-CSF, PGE-2 and lower IFN-α as compared to severe COVID-19 patients with low viral load (p < 0.05). CD14 + monocytes of COVID-19 patients with high viral load presented higher expression of PD-1 but lower HLA-DR on the cell surface than severe COVID-19 patients with low viral load. All COVID-19 patients presented decreased monocyte mitochondria membrane polarization, but high SARS-CoV-2 viral load was associated with increased mitochondrial reactive oxygen species. In this sense, higher viral load induces mitochondrial reactive oxygen species generation associated with exhaustion profile in CD14 + monocytes of severe COVID-19 patients. Altogether, these data shed light on new pathological mechanisms involving SARS-CoV-2 viral load on monocyte activation and mitochondrial function, which were associated with COVID-19 severity.
AB - Monocytes play a major role in the initial innate immune response to SARS-CoV-2. Although viral load may correlate with several clinical outcomes in COVID-19, much less is known regarding their impact on innate immune phenotype. We evaluated the monocyte phenotype and mitochondrial function in severe COVID-19 patients (n = 22) with different viral burden (determined by the median of viral load of the patients) at hospital admission. Severe COVID-19 patients presented lower frequency of CD14 + CD16- classical monocytes and CD39 expression on CD14 + monocytes, and higher frequency of CD14 + CD16 + intermediate and CD14-CD16 + nonclassical monocytes as compared to healthy controls independently of viral load. COVID-19 patients with high viral load exhibited increased GM-CSF, PGE-2 and lower IFN-α as compared to severe COVID-19 patients with low viral load (p < 0.05). CD14 + monocytes of COVID-19 patients with high viral load presented higher expression of PD-1 but lower HLA-DR on the cell surface than severe COVID-19 patients with low viral load. All COVID-19 patients presented decreased monocyte mitochondria membrane polarization, but high SARS-CoV-2 viral load was associated with increased mitochondrial reactive oxygen species. In this sense, higher viral load induces mitochondrial reactive oxygen species generation associated with exhaustion profile in CD14 + monocytes of severe COVID-19 patients. Altogether, these data shed light on new pathological mechanisms involving SARS-CoV-2 viral load on monocyte activation and mitochondrial function, which were associated with COVID-19 severity.
KW - CD39
KW - COVID-19
KW - HLA-DR
KW - Immune checkpoints
KW - PD-1
KW - Reactive oxygen species
UR - http://www.scopus.com/inward/record.url?scp=85127755814&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127755814&partnerID=8YFLogxK
U2 - 10.1016/j.intimp.2022.108697
DO - 10.1016/j.intimp.2022.108697
M3 - Article
C2 - 35405594
AN - SCOPUS:85127755814
SN - 1567-5769
VL - 108
JO - International immunopharmacology
JF - International immunopharmacology
M1 - 108697
ER -